Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 3:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 82 matching trials from the live ClinicalTrials.gov search.
Conditions
Thrombotic Thrombocytopenic Purpura
Interventions
Rituximab, Plasma exchange, Corticosteroids
Drug · Procedure
Lead sponsor
Carelon Research
Other
Eligibility
12 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
23
States / cities
Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 14 more
Conditions
Non-alcoholic Steatohepatitis, Chronic Liver Disease, HCV, NASH - Nonalcoholic Steatohepatitis, HIV Infection, Thrombocytopenia, Hepatitis C Virus, HBV, Human Immunodeficiency Virus, Liver Diseases, Hepatitis B Virus
Interventions
Eltrombopag, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
33
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 28 more
Conditions
Healthy, Transfusion Reactions
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Severe Malaria, Thrombocytopenia
Interventions
Whole blood transfusion
Other
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
1 Month to 59 Months
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Completed No phase listed Observational Accepts healthy volunteers

Clinical Performance Evaluation of T-TAS®01 HD Chip

NCT06087198
Conditions
Thrombocytopenia
Interventions
T-TAS 01 HD Assay
Diagnostic Test
Lead sponsor
Hikari Dx, Inc.
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
6
States / cities
San Francisco, California • Denver, Colorado • Baltimore, Maryland + 3 more
Conditions
Leukemia, Lymphoma
Interventions
Rituximab, 111In Ibritumomab, Planar Scintigraphy Imaging, 90Y IbritumomabTiuxetan, Fludarabine, Bendamustine, Thymoglobulin, Tacrolimus, Methotrexate, Mycophenolate, G-CSF, Stem Cell Transplantation
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Houston, Texas
Conditions
Transfusion Related Complication, Liver Transplant
Interventions
Donor Blood, Banked Blood
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Completed Not applicable Interventional Accepts healthy volunteers

Assessment of Whole Blood Cold Stored Platelets

NCT02006368
Conditions
Healthy
Interventions
Blood Collection and autologous re-infusion
Other
Lead sponsor
Bloodworks
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Acute Coagulopathy
Interventions
Blood product transfusion based on conventional coagulation tests., Blood product transfusion based on rapid thrombelastography (r-TEG) results.
Biological
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Platelet Refractoriness, Hematologic Malignancy
Interventions
isatuximab 10 mg/kg
Drug
Lead sponsor
Firas El Chaer, MD
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Multiple Myeloma, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, HDT-AHCT
Interventions
Romiplostim
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Not listed Phase 1 Interventional Accepts healthy volunteers

Cold Apheresis Platelets in PAS

NCT02754414
Conditions
Platelet Transfusion
Interventions
Apheresis platelet collection, Refrigerated storage of apheresis platelets in PAS/plasma, Infusion of aliquot of autologous radiolabeled platelets, In vitro tests
Procedure · Other · Radiation
Lead sponsor
Bloodworks
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Completed Phase 4 Interventional Results available

Immunomodulation Following Transfusion

NCT00810810
Conditions
Blood Component Transfusion
Interventions
Standard blood components, Leukoreduced blood components, Leukoreduced and irradiated
Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Seattle, Washington
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Reversal of Aspirin Antiplatelet Therapy With Cold Stored Platelets

NCT05111028
Conditions
Reversal of Platelet Aggregation Inhibitors
Interventions
Autologous Room Temperature stored Platelet transfusion, Autologous Cold Stored Platelet transfusion
Biological
Lead sponsor
Bloodworks
Other
Eligibility
18 Years to 59 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Neonatal Thrombocytopenia
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
0 Days to 6 Months
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Heart Valve Disease, Coronary Artery Disease
Interventions
Human fibrinogen concentrate, apheresis platelets
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 85 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Completed Phase 2 Interventional Results available

Cold Stored Platelet in Hemorrhagic Shock

NCT04667468
Conditions
Trauma, Hemorrhage
Interventions
Cold Stored Platelets (CSP), Standard Care
Biological
Lead sponsor
Jason Sperry
Other
Eligibility
15 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Jackson, Mississippi + 1 more
Terminated Phase 2 Interventional Results available

The SOLID Platelet Study

NCT03712618
Conditions
Platelet Transfusion Refractoriness (PTR), Thrombocytopenia
Interventions
Platelet Transfusion - LONG Platelet Transfusion, Platelet Transfusion - SHORT Platelet Transfusion
Biological
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 100 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Recruiting Not applicable Interventional Accepts healthy volunteers

Neonatal Platelet Transfusion Threshold Trial

NCT06676904
Conditions
Thrombocytopenia, Neonatal, Platelet Transfusion, Infant, Newborn, Diseases, Infant, Extremely Low Birth Weight, Infant, Small for Gestational Age, Thrombosis
Interventions
Higher Platelet Transfusion Threshold, Lower Platelet Transfusion Threshold
Procedure
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
1 Hour to 48 Hours
Enrollment
2,433 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2031
U.S. locations
20
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 17 more
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unusual Cancers of Childhood
Interventions
anti-thymocyte globulin, filgrastim, busulfan, carmustine, cyclophosphamide, cyclosporine, cytarabine, etoposide, fludarabine phosphate, melphalan, methotrexate, methylprednisolone, mycophenolate mofetil, tacrolimus, peripheral blood stem cell transplantation, umbilical cord blood transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 60 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Diffuse Large B-cell Lymphoma (DLBCL), Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Interventions
leukapheresis, Plerixafor, carmustine, etoposide, cytarabine, melphalan, Autologous Stem Cell Transplantation
Procedure · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
14
States / cities
Omaha, Nebraska • Basking Ridge, New Jersey • Middletown, New Jersey + 10 more
Conditions
Neoplasms, Thrombocytopenia, Multiple Myeloma, Lymphoma, Malignant
Interventions
(PN-152,243)/PN-196,444
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
6
States / cities
Berkeley, California • La Jolla, California • Los Angeles, California + 2 more
Conditions
Thrombocytopaenia
Interventions
Eltrombopag, Azacitidine, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Hartford, Connecticut • Atlanta, Georgia • Chicago, Illinois + 7 more
Completed Phase 4 Interventional Results available

ECMO Hemostatic Transfusions in Children

NCT05796557
Conditions
Extracorporeal Membrane Oxygenation Complication, Hemorrhage, Thromboembolism, Transfusion Adverse Reaction
Interventions
Platelet Transfusion
Biological
Lead sponsor
Yale University
Other
Eligibility
Up to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
9
States / cities
Atlanta, Georgia • Iowa City, Iowa • Louisville, Kentucky + 5 more